Skip to main content
Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc. — Investor Relations & Filings

Ticker · PRAX ISIN · US74006W2070 US Manufacturing
Open in API
Filings indexed 458 across all filing types
Latest filing 2021-05-14 Capital/Financing Update
Country US United States of America
Listing US PRAX

About Praxis Precision Medicines, Inc.

https://praxismedicines.com/

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company that develops therapies for central nervous system (CNS) disorders. The company's methodology involves translating insights from genetic epilepsies into treatments for conditions characterized by neuronal excitation-inhibition imbalance. Praxis employs a genetics-focused approach, utilizing translational tools and patient-guided development strategies to advance its portfolio. The developmental pipeline includes several clinical-stage assets and numerous early-stage programs designed to address complex brain disorders.

Recent filings

Filing Released Lang Actions
424B4
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus for a public offering of common stock by Praxis Precision Medicines, Inc. It includes information about the offering size, underwriting, company overview, business strategy, pipeline, and clinical trial updates. The document is a registration statement filed pursuant to Rule 424(b)(4) under the Securities Act, which is a prospectus supplement related to a capital raising event. It is not a financial report, earnings release, or management discussion, but rather a capital markets document focused on the offering of new shares to investors. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full prospectus rather than a brief announcement or regulatory filing.
2021-05-14 English
Regulatory Filings 2021
Regulatory Filings
2021-05-14 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Securities and Exchange Commission regarding a Registration Statement on Form S-1 for Praxis Precision Medicines, Inc. It requests acceleration of the effective date of the Registration Statement under Rule 461 of the Securities Act of 1933. The letter is signed by representatives of underwriters. The content is related to the registration and offering process of securities, specifically an acceleration request for a registration statement effectiveness. This is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration and offering process. The document is short (1687 characters) and is a formal correspondence with the SEC, fitting the category of Regulatory Filings (RNS).
2021-05-11 English
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It is a formal correspondence related to the regulatory process of securities registration, specifically under the Securities Act of 1933. The content is a procedural request and does not contain financial data, report content, or detailed disclosures typical of financial reports. The document length is short (1911 characters), and it is clearly an announcement/request related to a regulatory filing rather than the filing itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-05-11 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes detailed information about the company, the offering, risk factors, use of proceeds, and other disclosures typical of an IPO or public offering registration statement. It is not an annual report, earnings release, or any other financial report type. It is a capital markets filing related to fundraising and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, confirming it is not a mere announcement or notice but the actual registration statement.
2021-05-11 English
10-Q
Interim / Quarterly Report Q1 2021
2021-05-11 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.